Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fulcrum Therapeutics ( (FULC) ) has provided an announcement.
On July 29, 2025, Fulcrum Therapeutics announced promising results from the 12 mg dose cohort of its Phase 1b clinical trial of pociredir for sickle cell disease. The trial showed significant increases in fetal hemoglobin and improvements in key markers of hemolysis and anemia, with pociredir being well-tolerated and no serious adverse events reported. These findings suggest potential benefits in reducing vaso-occlusive crises and improving patient outcomes, positioning Fulcrum favorably in the biopharmaceutical industry. The company also reported a cash runway into 2028, despite a net loss in the second quarter of 2025.
The most recent analyst rating on (FULC) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Fulcrum Therapeutics stock, see the FULC Stock Forecast page.
Spark’s Take on FULC Stock
According to Spark, TipRanks’ AI Analyst, FULC is a Neutral.
Fulcrum Therapeutics’ overall stock score is driven primarily by strong technical momentum and a healthy balance sheet. However, ongoing profitability challenges and a low valuation score temper the outlook. Positive clinical trial developments and strong cash reserves provide some optimism, but the company’s financial performance remains a critical area for improvement.
To see Spark’s full report on FULC stock, click here.
More about Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases. The company’s lead clinical program is pociredir, aimed at treating sickle cell disease (SCD) by increasing fetal hemoglobin levels.
Average Trading Volume: 663,216
Technical Sentiment Signal: Buy
Current Market Cap: $421.6M
See more data about FULC stock on TipRanks’ Stock Analysis page.